Perioperative prophylaxis with ertapenem reduced infections caused by extended-spectrum betalactamase-producting Enterobacteriaceae after kidney transplantation by Sanclemente, Gemma et al.
RESEARCH ARTICLE Open Access
Perioperative prophylaxis with ertapenem




Gemma Sanclemente1, Marta Bodro1*, Carlos Cervera1, Laura Linares1, Frederic Cofán2, Francesc Marco3,
Jordi Bosch3, Federico Oppenheimer2, Fritz Dieckmann2 and Asunción Moreno1
Abstract
Backgound: In recent years we have witnessed an increase in infections due to multidrug-resistant
organisms in kidney transplant recipients (KTR). In our setting, we have observed a dramatic increase in
infections caused by extended-spectrum betalactamase-producing (ESBL) Enterobacteriaceae in KTR. In 2014
we changed surgical prophylaxis from Cefazolin 2 g to Ertapenem 1 g.
Methods: We compared bacterial infections and their resistance phenotype during the first post-transplant
month with an historical cohort collected during 2013 that had received Cefazolin.
Results: During the study period 110 patients received prophylaxis with Cefazolin and 113 with Ertapenem.
In the Ertapenem cohort we observed a non-statistically significant decrease in the percentage of early
bacterial infection from 57 to 47%, with urine being the most frequent source in both. The frequency of
infections caused by Enterobacteriaceae spp. decreased from 64% in the Cefazolin cohort to 36% in the
Ertapenem cohort (p = 0.005). In addition, percentage of ESBL-producing strains decreased from 21 to 8% of
all Enterobacteriaceae isolated (p = 0.015). After adjusted in multivariate Cox regression analysis, male sex (HR
0.16, 95%CI: 0.03–0.75), cefazolin prophylaxis (HR 4.7, 95% CI: 1.1–22.6) and acute rejection (HR 14.5, 95% CI:
1.3–162) were associated to ESBL- producing Enterobacteriaceae infection.
Conclusions: Perioperative antimicrobial prophylaxis with a single dose of Ertapenem in kidney transplant
recipients reduced the incidence of early infections due to ESBL-producing Enterobacteriaceae without
increasing the incidence of other multidrug-resistant microorganisms or C. difficile.
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Background
Infections are a major complication after kidney trans-
plantation (KT). During the first post-transplant month,
the majority of infections are caused by bacteria, most of
them originating from the urine [1]. In recent years we
have observed an increase in the incidence of infections
caused by multidrug-resistant microorganisms, especially
ESBL-producing Enterobacteriaceae [2]. These infections
have been associated not only with increased costs, but
also with higher mortality and graft loss [3, 4]. Peri-
operative prophylaxis is administered to prevent surgical
site infections but, in the case of urological procedures,
it also helps prevent postoperative bacteriuria. Classically
guidelines recommend a single dose of Cefazolin in
clean-contaminated surgical procedures, as is the case
for kidney transplantation [5]. In our centre we have ob-
served a high incidence of early infections caused by
ESBL Enterobacteriaceae; the prevalence of infections
caused by ESBL-producing Enterobacteriaceae in 2012
in kidney transplant recipients was 12%, mainly urinary
tract infections (80%). For this reason, and based on the
published data on the efficacy and safety of Ertapenem
for surgical prophylaxis [6], we decided to change the
antimicrobial prophylaxis for KT patients from Cefazolin
2 g to Ertapenem 1 g.
The aim of this study was to compare the incidence
and susceptibility profile of bacterial infections in the
first month after KT between patients who received
Cefazolin and those who received Ertapenem.
Methods
We conducted an observational study at a tertiary
university referral hospital with an active kidney
transplantation programme (annual average of 120 pro-
cedures) in Barcelona, Spain. Until December 2013 all
kidney transplant patients received a single dose of
Cefazolin 2 g as perioperative antimicrobial prophylaxis.
From January 2014 all patients undergoing KT received
a single dose of Ertapenem 1 g. Although ertapenem re-
quires a scaled dose adjustment in renal dysfunction in
case of treatment, we do not consider adjustment be-
cause perioperative antimicrobial prophylaxis consists in
a single dose of antibiotic. We collected data on all
bacterial infections that occurred during the first post-
transplant month, and compared patients who received
a KT during 2013 (Cefazolin group, historical cohort)
and patients undergoing KT during 2014 (Ertapenem
group). Data was prospectively recorded from January to
December 2014 and data from the historical cohort was
collected retrospectively. Patients who received other
perioperative antimicrobial prophylaxis were excluded.
Cotrimoxazole was prescribed in all recipients for the
prevention of Pneumocystis jirovecii pneumonia, given
from the first day of oral tolerance until the sixth month
post-transplantation. Double transplants were excluded.
During the first month after transplantation follow-up
was performed weekly. We routinely collect urine cul-
tures after urinary catheter removal. Ureteral stents were
only used in orthotopic transplantation (< 5% of all pro-
ceedings). Eighty-one kidney recipients received the
monoclonal anti-IL2 receptor antagonist basiliximab
therapy and 115 received rabbit anti-thymocyte globulin
(ATG) as induction therapy. All patients received
Corticosteroids and dose was progressively decreased
from initially 1 mg/kg/day to 5 mg/day at 3 months post-
transplantation. Mycophenolate mofetil (MMF) or
sirolimus with tacrolimus or cyclosporine were mainten-
ance immunosupression.
Definitions
Urinary tract infection (UTI) was diagnosed based on
the guidelines of the European Society of Clinical Micro-
biology and Infectious Disease Infectious Diseases Soci-
ety of America [7, 8] and Guidelines from the American
Society of Transplantation Infectious Diseases Commu-
nity of Practice [9]. Asymptomatic bacteriuria was de-
fined when more than 100.000 UFC/mL of urinary
pathogens were found in aseptically collected midstream
urine in absence of symptomatology. Acute uncompli-
cated UTI (including cystitis and prostatitis) was defined
when recipients presented urinary frequency/urgency,
dysuria, suprapubic pain but no indwelling device and
no systemic symptoms such as fever, allograft pain or
hemodynamic compromise were present, and a urine
culture yielding growth of more than 100.000 CFU/mL
of urinary pathogens. Complicated UTI, including acute
graft pyelonephritis or upper tract UTI, was defined as
at least one of the following: malaise, chills, fever,
hemodynamic instability, leukocytosis, pain over the
allograft or the costovertebral angles for allograft or na-
tive kidney involvement, bacteremia with the same
organism identified in urine culture and a significant
growth of a uropathogen (≥10.000 CFU/mL).
Surgical site infection (SSI) was defined as those
involving only skin and incisional subcutaneous tissue.
Deep incisional SSI was present when involving deep tis-
sues, including also infections draining through incision.
Organ/space SSI was considered if involving any part of
the anatomy in organs and spaces manipulated during
transplant surgery [10].
Venous catheter-related bloodstream infection was de-
fined as the presence of bacteremia originating from an
intravenous catheter when documenting a blood isolated
cultured from the catheter tip using the Maki’s semiquan-
titative rollplate catheter culture (≥ 15 CFU). Primary or
unknown source bacteremia was considered when a one
or more blood cultures and organism cultured from blood
was not related to an infection at another site.
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Patients with septic shock can be identified by pre-
senting a systolic pressure < 90 mmHg that was unre-
sponsive to fluid therapy or required vasoactive drug
treatment.
All patients diagnosed of acute allograft rejection had bi-
opsy. If kidney recipients required definitive hemodialysis,
graft loss was considered.
We used Magiorakos et al. [11] criteria to defined multi-
drug resistance (MDR). Briefly, we considered Enterobac-
teriaceae and Pseudomonas aeruginosa to be MDR when
a strain was resistant to one or more agent in three or
more antimicrobial categories normally active against the
isolated bacteria. For S. aureus, methicillin-resistant
strains were considered MDR.
Microbiological studies
Matrix-Assisted Laser Desorption/Ionization Time of Flight
(MALDI-TOF) technique was performed to identify micro-
organisms. Susceptibility testing of microorganisms
recovered was done using the Phoenix automated system
(Becton Dickinson Company, Sparks, Maryland), E-test or
Kirby-Bauer disc-diffusion methods. To define susceptibility
or resistance to antimicrobial agents we used the criteria of
the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) available at the time of diagnosis. Ex-
tended spectrum beta-lactamases (ESBLs) are defined as
enzymes produced by certain bacteria that are able to
hydrolyze extended spectrum cephalosporin and aztreonam
(but not the cephamycins or carbapenems) and which are
inhibited by β-lactamase inhibitors such as clavulanic acid
[12]. EUCAST guidelines were followed in case of ESBL or
a carbapenemase production suspiction [13, 14].
Statistical analysis
We used SPSS statistical package (version 18.0; SPSS,
Chicago, Illinois, USA) to perform statistical analysis,
using the χ2 or Fischer exact test when comparing cat-
egorical variables and the Student t test or non-parametric
tests depending on the homogeneity of the variable to
compare continuous variables. We used Kaplan-Meier
method to perform survival curves. We assessed the im-
pact of age, sex, prior transplantation, prophylaxis group,
reoperation, acute allograft rejection, diabetes mellitus and
post transplant hemodyalisis requirement on presenting
infection caused by ESBL-producing Enterobacteriaceae
using Cox proportional hazards regression model to cal-
culate hazard ratios (HRs) and 95% confidence intervals
(CIs). All statistical tests were two-tailed, and the thresh-
old of statistical significance was set at p < 0.05.
Results
During the study period, 110 patients received prophy-
laxis with Cefazolin and 113 with Ertapenem. We found
no differences in the baseline pre-transplant variables,
immunosuppression, non-infectious post-transplant
complications or the incidence of early infection be-
tween cohorts (Table 1).
Outcomes are described in Table 2. Sixty-three pa-
tients in the Cefazolin group (57%) developed at least
one episode of bacterial infection during the first month
after transplantation compared to 53 patients (47%) in
the Ertapenem group (p = 0.1). Ten patients of the Cefa-
zolin group and 11 in the Ertapenem group presented
two or more episodes of bacterial infection respectively.
When we analysed only clinically significant infections
(excluding asymptomatic bacteriuria from the analysis),
the incidence was similar in both cohorts (26% in those
who received Cefazolin and 20% in those who received
Ertapenem, p = 0.2). Median days until urinary catheter
removal were 9 (IQR 4–48).
If excluding asymptomatic bacteriuria, the timeline to
the occurrence of a first infection after transplantation
did not differ between groups (mean 10 days). The main
source of infection was the urinary tract in both groups
(85 and 70% in the Cefazolin and Ertapenem groups re-
spectively, p = 0.09). Ten episodes (14%) in the Cefazolin
group and eight (12%) in the Ertapenem group had posi-
tive blood cultures (p = 0.43). Regarding microbiology of
bacteremic episodes, 28% were caused by P. aeruginosa,
followed by E.coli (22%), K. pneumoniae (22%) and
Staphylococci (11%). Regarding bacteremic episodes, the
most important source of infection was urinary in the
Cefalozin group (6 patients) and the venous catheter (4
patients) in the Ertapenem group respectively. Moreover,
two episodes of bacteremia in the Cefazolin group and
none in the Ertapenem group were produced by MDR
organisms. There was no difference between the two
groups in terms of post-transplant complications, graft
lost or mortality at 30 days.
Regarding infection foci, 34% of episodes of urinary tract
infections were caused by E.coli, followed by Enterococcus
spp. (34%), P. aeruginosa (7%) and K. pneumoniae (1%).
Main aetiologies of SSI were Enterococcus spp. (34%),
E.coli (33%) and S. aureus (22%).
We also performed a subanalysis of patients presenting
with an ESBL-producing Enterobacteriaceae infection
the first month after transplantation. All patients except
4 had urinary cultures within 2 months before trans-
plantation (in case of residual diuresis). None of them
had presented an infection caused by ESBL-producing
Enterobacteriaceae prior transplantation.
We found no differences between groups regarding
the incidence of infections caused by Pseudomonas
aeruginosa (12% vs 14%, p = 0.9), Enterococcus spp.
(33% vs 47%, p = 0.1), Candida spp. (9% vs 5%, p =
0.1) or Clostridium difficile (1% vs 2%, p = 1). E. fae-
cium was isolated more frequently in the Cefazolin
group (54%) than in the Ertapenem group (26%, p =
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0.03), but none of the isolates were resistant to
vancomycin. We did not detect any carbapenem-
resistant Enterobacteriaceae. All episodes of Candida
spp. infections were UTI. Only one episode of candi-
demia was diagnosed during the study period (in the
group of ertapenem prophylaxis). Table 3 summarizes
the characteristics of the infectious episodes.
Multivariate cox regression analysis to evaluate risk for
ESBL-producing Enterobacteriaceae infection among
kidney recipients depending on some variables was per-
formed in Table 4. According to HR figures, male sex
(HR 0.16, 95% CI: 0.03–0.75), cefazolin prophylaxis (HR
4.7, 95% CI: 1.1–22.6) and acute allograft rejection (HR
14.5, 95% CI: 1.3–162) were associated to ESBL- produ-
cing Enterobacteriaceae infection. Nevertheless, age < 50
years (HR 0.5, 95% CI: 0.1–2.7), diabetes mellitus (HR
0.9, 95% CI: 1.6–5.7), post-transplant haemodyalisis (HR
0.3, 95% CI: 0.06–1.2), nephrostomy requirement (HR
0.8, 95% CI: 1.3–0.1) and reoperation (HR 2.6, 95% CI:
0.6–12) could not be considered risk factors for ESBL-
producing Enterobacteriaceae infection.
Regarding the aetiology of infectious episodes, we ob-
served a significantly higher number of episodes caused
by Enterobacteriaceae spp. in the Cefazolin group (47
episodes, 64% of all isolates) than in the Ertapenem
group (24 epidodes, 36%) (p = 0.005). In addition, a
higher percentage of isolates of Enterobacteriaceae spp.
were ESBL-producers in the Cefazolin group (10 epi-
sodes, 21%) comparing with the Ertapenem cohort (2
episodes, 8%, p = 0.01).
Table 1 Clinical characteristics of the cohort according to prophylaxis received
Variable Cefazolin (n = 110) Ertapenem (n = 113) P
Age in years (mean, ±SD) 54.02 (13.6) 53.99 (14.7) 1
Male sex 61 (55%) 65 (57%) 0.7
Donor type
Deceased 53 (48%) 61 (54%) 0.4
Live 57 (52%) 52 (46%)
Donor’s cause of death
Anoxia 14 (26%) 8 (15%) 0.1
CVA 31 (58%) 42 (80%)
Trauma 7 (13%) 2 (4%)
Other 1 (2%) 0
Median ischemia time (minutes, ±SD) 473 (470) 491 (434) 0.4
Diabetes mellitus 24 (22%) 26 (23%) 0.8
End-stage renal disease
Glomerulonephritis 9 (8%) 6 (5%) 0.9
Diabetes mellitus 17 (16%) 17 (16%)
Hypertension 19 (17%) 16 (14%)
Cystic kidney disease 18 (16%) 17 (15%)
Other Urologic 8 (7%) 10 (9%)
Other cause 23 (21%) 23 (20%)
Unkown/missing 16 (15%) 24 (21%)
Prior transplantation 18 (16%) 22 (19%) 0.6
Immunosuppression regimen
CNI + MMF+ CS 72 (65%) 64 (57%) 0.3
CNI + mTOR+ CS 34 (31%) 46 (41%)
Other 4 (4%) 3 (2%)
Induction
None 18 (16%) 9 (8%) 0.4
Basiliximab 26 (24%) 55 (49%)
Anti-lymphocyte globulines 66 (60%) 49 (43%)
Pre-transplant rituximab 13 (12%) 13 (11%) 0.9
CVA Cerebrovascular accident, CNI Calcineurin inhibitors, MMF Mycophenolate mofetil, mTOR Inhibitors of mammalian target of rapamycin, CS Corticosteroids
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The occurrence of ESBL-producing Enterobacteriaceae
infections was not related to an active outbreak of noso-
comial infection.
Figures 1 and 2 shows the Kaplan-Meier curves for
probability of early infections and ESBL-producing En-
terobacteriaceae infections respectively, by antibiotic
prophylaxis received. Patients with Ertapenem prophylaxis
presented fewer early infections (47%) than those with
Cefazolin prophylaxis (57%) but not reaching statistical
significance (log-rank, p = 0.1). Patients with Ertapenem
prophylaxis presented fewer infections caused by ESBL-
producing Enterobacteriaceae (8%) than those with Cefa-
zolin prophylaxis (21%) (log-rank, p = 0.01).
None of the infections could be considered a donor-
derived infection.
Graft loss at a 2-years follow-up was 4 and 7% between
cefazolin and ertapenem group respectively (p = 0.2). Mor-
tality at a 2-years follow-up was 7 and 4% comparing
cefazolin and ertapenem group respectively (p = 0.4).
Discussion
In this large cohort of adult kidney transplant recipients,
we found that perioperative antimicrobial prophylaxis
with a single dose of Ertapenem reduced the incidence
by almost half of Enterobacteriaceae infections and,
more importantly, that the incidence of ESBL-producing
strains decreased significantly by a third compared to
the use of a single dose of Cefazolin in the first moth
post transplantation.
The main goal of perioperative prophylaxis is to re-
duce surgical site infections. According to the recent
American guidelines on antimicrobial surgical prophy-
laxis, KTR should receive a single dose of Cefazolin 2g5.
However, a study performed during the 1990s found no
differences in the incidence of early infection in KT pa-
tients who received perioperative prophylaxis and those
who did not, suggesting that surgical prophylaxis can be
avoided in KT patients [15]. More recently, some au-
thors suggested using prophylaxis only in patients with a
higher risk of surgical site infection, such as recipients
older than 65 years or with a body mass index higher
than 35 [16]. Regardless of all of these considerations, in
our cohort of KT recipients the incidence of surgical site
infection was 4%, and was not the main route of early
infection. Instead, UTI were the most frequent type of
infection, as in many previous studies [17, 18].
Table 2 Outcomes of patients depending on perioperative antibiotic prophylaxis
Variable Cefazolin (n = 110) Ertapenem (n = 113) P
Post-transplant complications (first month)
Acute rejection 21 (19%) 15 (13%) 0.2
Haemodialysis 18 (16%) 25 (22%) 0.3
Reoperation 14 (13%) 12 (11%) 0.4
Nephrostomy 6 (5%) 6 (5%) 1
Ureteral stent 4 (4%) 11 (10%) 0.06
Days of urinary catheter removal (mean, SD) 9 (6) 9 (6) 0.8
Patients with infection (first month) 63 (57%) 53 (47%) 0.1
Patients with clinically significant infection (first month)a 29 (26%) 22 (20%) 0.2
Days until first infection (mean, SD) 10 (7) 11 (7) 0.7
Graft lost (30 days) 0 2 (2%) 1
Mortality (30 days) 0 1 (1%) 0.9
aClinically significant infection: excluding asymptomatic bacteriuria
Table 3 Differences in clinical and microbiological
characteristics of infectious episodes between the two cohorts
Variable Cefazolin (n = 73) Ertapenem (n = 67) P
Source of infection
Urinary 62 (85%) 47 (70%) 0.09
SSI 3 (4%) 6 (9%) 0.5
Other 8 (11%) 14 (21%) 0.3
Positive blood cultures 10 (14%) 8 (12%) 0.4
Septic shock 2 (3%) 1 (2%) 0.6
Isolated microorganisms
Enterobacteriaceae 47 (64%) 24 (36%) 0.005
ESBL-producing 10 (21%)a 2 (8%)b 0.01
P. aeruginosa 9 (12%) 9 (14%) 1
XDR 5 (56%) 2 (22%) 0.2
Enterococcus spp. 24 (33%) 31 (47%) 0.1
E. faecium 13 (54%) 8 (26%) 0.03
C. difficile colitis 1 (1%) 2 (3%) 1
Candida spp. infection 7 (9%) 3 (5%) 0.1
CR Enterobacteriaceae 0 0
ESBL Extended-spectrum betalactamase-producing, XDR Extensively drug-
resistant, CR Carbapenem-resistant
aseven episodes were due to Klebsiella pneumoniae and three to E.coli
ball episodes were due to Klebsiella pneumoniae
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Interestingly, we observed a trend towards a lower
incidence of infections during the first month post-
transplantation using a single dose of Ertapenem, especially
UTI. Furthermore, we observed a significant reduction in
the incidence of infections due to Enterobacteriaceae and,
more importantly, those strains producing ESBL. It is well
known that ESBL-producing Gram-negative enteric bacilli
infections after KT are associated with a worse prognosis
for both the graft and patient and a high risk of UTI
recurrence [4, 19]. Similar to our results, a Brazilian study
described a reduction in the incidence of early UTI after
KT when adding gentamycin to the usual prophylaxis [20].
However, the use of aminoglycosides in the early period
after KT is not desirable due to its potential nephrotoxicity.
In contrast, prolonging the duration of prophylaxis seems
to have no impact on the occurrence of surgical site infec-
tion and UTI [21]. Moreover, Ertapenem is efficacious and
safe for the prophylaxis of patients with abdominal surgery
including colorectal manipulation [6, 22, 23]. Bora et al.
[24] recommend tacrolimus concentration monitoring and
Table 4 Multivariate cox regression analysis of risk factors for ESBL-producing Enterobacteriaceae infection among kidney recipients
depending on some variables
Variable ESLB-producing Enterobacteriaceae infection HR (95%CI) P
Yes No
Age
< 50 years 2 (17%) 0.5 (0.1–2.7) 0.5
≥ 50 years 10 (83%) 62 (60%)
Sex
Male 2 (17%) 58 (56%) 0.16 (0.03–0.75) 0.02
Female 10 (83%) 46 (44%)
Diabetes mellitus
Yes 2 (17%) 80 (77%) 0.9 (1.6–5.7) 0.9
No 10 (83%) 24 (23%)
Prior transplantation
Yes 3 (25%) 86 (83%) 5.8 (1.2–30) 0.04
No 9 (75%) 18 (17%)
Prophylaxis group
Cefazolin 10 (83%) 53 (51%) 4.7 (1.1–22.6) 0.05
Ertapenem 2 (17%) 51 (49%)
Acute allograft rejection
Yes 1 (8%) 26 (25%) 14.5 (1.3–162) 0.03
No 11 (92%) 78 (75%)
Post-transplant Haemodialysis
Yes 3 (25%) 26 (25%) 0.3 (0.06–1.2) 0.09
No 9 (75%) 78 (75%)
Nephrostomy
Yes 1 (8%) 8 (8%) 0.8 (1.3–0.1) 0.8
No 11 (92%) 96 (92%)
Reoperation
Yes 3 (25%) 11 (11%) 2.6 (0.6–12) 0.2
No 9 (75%) 93 (89%)
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dose reductions when the two drugs are administered in
combination. Nevertheless perioperative prophylaxis con-
sists in a single dose of ertapenem before surgery and pa-
tients usually start tacrolimus 24 h after surgery, so we
think that adjustments may not be necessary. To the best
of our knowledge, this is the first study analysing the effi-
cacy of Ertapenem for the surgical prophylaxis of KT
recipients.
Other variables associated with infections caused by
ESBL-producing Enterobacteriaceae were prior transplant-
ation, acute allograft rejection and female gender. It has
been reported that the relative faecal abundance of ESBL E.
coli is associated with UTI in women who have not been
exposed to antibiotics [25]. Prior transplantation and acute
allograft rejection may act as surrogate markers for other
variables that might increase the probability of colonization
by these organisms, such as antibiotic exposure and health
care relationship, as others have found [26, 27], or even re-
flect a overimmunosuppression state that favors infection.
Most studies agree that the Enterobacteriaceae causing
UTI are ascending infections coming from the bowel after
a previous colonization. In the setting of transplantation,
Bert et al. found that pre-transplant faecal carriage of ESBL
Enterobacteriaceae was an independent risk factor for
infections caused by these organisms after liver transplant-
ation [28], while a reduction in infections caused by Gram-
negative bacteria was documented after selective bowel
decontamination [29].
Fig. 1 Kaplan–Meier survival graph for probability of early infections (first post transplantation month) by perioperative antibiotic prophylaxis.
Patients with Ertapenem prophylaxis presented fewer early infections (47%) than those with Cefazolin prophylaxis (57%) but not reaching
statistical significance (log-rank, p = 0.1)
Fig. 2 Kaplan–Meier survival graph for probability of ESBL- producing Enterobacteriaceae infection (first post transplantation month) by
perioperative antibiotic prophylaxis. Patients with Ertapenem prophylaxis presented fewer infections caused by ESBL-producing Enterobacteriaceae
(8%) than those with Cefazolin prophylaxis (21%) (log-rank, p = 0.01)
Sanclemente et al. BMC Nephrology          (2019) 20:274 Page 7 of 10
The main concern over administering broad-spectrum
antibiotics is the development of infections caused by
drug-resistant organisms. However, data about anti-
microbial resistance in Pseudomonas aeruginosa infec-
tions showed a significant increase of antimicrobial
resistance at 3 days of antibiotic administration [30, 31].
Likewise, we previously reported that one of the risk fac-
tors for infections with ESBL enteric bacilli in KT
recipients was the prescription of antibiotics in addition
to habitual prophylaxis [32]. Although Itani et al.
reported a higher incidence of C. difficile infection in pa-
tients submitted to colorectal surgery who received
prophylaxis with Ertapenem [6], we found no evidence
of an increase in C. difficile infection, P. aeruginosa or
carbapenem-resistant Enterobacteriaceae. A recent sur-
veillance study also reported that the use of Ertapenem
is not associated with an increase in drug-resistant
Gram-negative bacilli [33].
A surprising result of our study was the decline in the
occurrence of E. faecium infections in the Ertapenem co-
hort. It is well known that the activity of Ertapenem
against Enterococcus faecalis is marginal and that E. fae-
cium is resistant to all betalactams [34]. However, some
years ago Mainardi et al. reported that imipenem could
inhibit the synthesis of E. faecium peptidoglycan [35].
More recently, Dubée et al. reported this property for
Ertapenem although its activity is lower than imipenem
[36]. These studies analysed only the molecular basis of
these interactions, but no study has evaluated its impact
in the clinical setting. Nevertheless we hypothesize that
the lower incidence of E. faecium and P. aeruginosa in
the Ertapenem group were either random events or pos-
sibly due to an unknown factor not included in the
analysis.
In recent years we have observed in our kidney trans-
plant unit an increase in the incidence of infections caused
by multidrug-resistant microorganisms, especially ESBL-
producing Enterobacteriaceae and similar data has pub-
lished in other centres worldwide [37–39]. Infections
caused by multidrug-resistant pathogens caused an in-
creasing number of healthcare-associated infections, caus-
ing a significant increment in costs and morbidity and
mortality and are often associated with ICU admission
and prior antibiotic use [40].
Reducing Enterobacteriaceae infections, especially ESBL-
producing strains could mean reducing hospitalization and
costs. However, in a long-term analysis, there was no statis-
tical difference in 2-year graft loss neither 2-year mortality
between the groups of prophylaxis. To avoid infection and
especially colonization due to drug-resistant organisms
some strategies have been described. First of all, shortening
antibiotic regimens so as to decrease antibiotic-related se-
lective pressures could be important prophylactic steps. Spe-
cifically, European guidelines recommend educational
programmes based on hand hygiene, environmental clean-
ing, contact precautions and antimicrobial stewardship to
reduce the horizontal spread of multidrug-resistant organ-
isms during hospitalisation [41].
Our study had several limitations. First, as it was con-
ducted in a single hospital ward, the results may not be
applicable to other centres with different epidemiological
backgrounds. Second, we did not perform a study of fae-
cal carriage at the time of transplantation and, thus, we
cannot rule out the possibility that the differences in the
incidence of infections with Enterobacteriaceae between
groups were due to different rates of pre-transplant
bowel colonization. Furthermore, the combination of
retrospective and prospective assessments limits the
ability to truly compare the groups as it fails to consider
the potential for local confounders in practices and epi-
demiologic changes. Moreover, we have no information
about prior antibiotic exposure before transplantation.
Although there were no changes in infection control
protocol neither in surgical techniques or pre-transplant
management during the study period, there could be po-
tential pitfalls inherent in a comparison of two different
eras. So, this data should be used to inform future more
rigorous studies, including randomized ones.
Conclusion
In conclusion, a single perioperative prophylactic dose of
Ertapenem in KT was effective at preventing surgical site
infection and decreased the incidence of infections due
to Enterobacteriaceae during the first post-transplant
month, with a particular impact on ESBL-producing
strains and E. faecium. The use of Ertapenem did not in-
crease the incidence of other drug-resistant microorgan-
isms as P. aeruginosa, C. difficile, Candida spp. or
carbapenem-resistant Enterobacteriaceae.
Abbreviations
ESBL: Extended-spectrum betalactamase-producing; KT: Kidney
transplantation; KTR: Kidney transplant recipients; MDR: Multidrug-resistant;
UTI: Urinary tract infection
Acknowledgements
This work was supported by the “Red Española de Investigación en Patología
Infecciosa” (REIPI, RD06/0008/1013).
Authors’ contributions
All authors participated in research design, in the writing of the paper, in the
performance of the research and in data analysis. Moreover, they have been
involved in drafting the manuscript and revising it and they have given the
final approval of the version to be published. Finally, they also agree to be
accountable for all aspects of the work in ensuring that questions related to
the accuracy or integrity of any part of the work are appropriately
investigated and resolved.
Funding
The authors have not received any funding for the conduct of this study.
Sanclemente et al. BMC Nephrology          (2019) 20:274 Page 8 of 10
Availability of data and materials
Clinical data were prospectively or retrospectively recorded depending on
the time period and introduced into a database with coded names to
maintain anonymity.
Ethics approval and consent to participate
The study was approved by our institution’s Ethics Committee. All patients
signed an informed consent before undergoing kidney transplantation that




The authors declare that they have no competing interests.
Author details
1Department of Infectious Diseases, Hospital Clinic – IDIBAPS, University of
Barcelona, Villarroel 170, 08036 Barcelona, Spain. 2Kidney Transplant Unit,
Hospital Clinic – IDIBAPS, University of Barcelona, Barcelona, Spain.
3Department of Microbiology, Centre Diagnòstic Biomèdic (CDB), Instituto de
Salud Global de Barcelona (ISGlobal), Hospital Clinic – IDIBAPS, University of
Barcelona, Barcelona, Spain.
Received: 15 March 2019 Accepted: 9 July 2019
References
1. Dorschner P, McElroy LM, Ison MG. Nosocomial infections within the first
month of solid organ transplantation. Transpl Infect Dis. 2014;16:171–87.
2. Cervera C, van Delden C, Gavaldà J, et al. ESCMID study group for infections
in compromised hosts. Multidrug-resistant bacteria in solid organ transplant
recipients. Clin Microbiol Infect. 2014;20(Suppl 7):49–73.
3. Evans HL, Lefrak SN, Lyman J, et al. Cost of gram-negative resistance. Crit
Care Med. 2007;35(1):89–95.
4. Linares L, Cervera C, Cofán F, et al. Epidemiology and outcomes of multiple
antibiotic-resistant bacterial infection in renal transplantation. Transpl Proc.
2007;39:2222.
5. Bratzler DW, Dellinger EP, Olsen KM, American Society of Health-System
Pharmacists (ASHP), Infectious Diseases Society of America (IDSA), Surgical
Infection Society (SIS), Society for Healthcare Epidemiology of America
(SHEA), et al. Clinical practice guidelines for antimicrobial prophylaxis in
surgery. Surg Infect. 2013;14(1):73–156.
6. Itani KM, Wilson SE, Awad SS, et al. Ertapenem versus cefotetan prophylaxis
in elective colorectal surgery. N Engl J Med. 2006;355(25):2640–51.
7. Hooton TM, Bradley SF, Cardenas DD, Infectious Diseases Society of
America, et al. Diagnosis, prevention, and treatment of catheter-associated
urinary tract infection in adults: 2009 international clinical practice
guidelines from the Infectious Diseases Society of America. Clin Infect Dis.
2010;50(5):625–63.
8. Gupta K, Hooton TM, Naber KG, Infectious Diseases Society of America,
European Society for Microbiology and Infectious Diseases, et al.
International clinical practice guidelines for the treatment of acute
uncomplicated cystitis and pyelonephritis in women: a 2010 update by the
Infectious Diseases Society of America and the European Society for
Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103–20.
9. Goldman JD, Julian K. Urinary tract infections in solid organ transplant
recipients: guidelines from the American Society of Transplantation
Infectious Diseases Community of Practice. Clin Transplant. 2019:e13507.
https://doi.org/10.1111/ctr.13507.
10. National Nosocomial Infections Surveillance (NNIS) report, data summary
from October 1986–April 1996, issued May 1996. A report from the National
Nosocomial Infections Surveillance (NNIS) System. Am J Infect Control. 1996;
24(5):380–8.
11. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively
drug-resistant and pandrug-resistant bacteria: an international expert
proposal for interim standard definitions for acquired resistance. Clin
Microbiol Infect. 2012;18(3):268–81.
12. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical
update. Clin Microbiol Rev. 2005;18:657–86.
13. European Committee on Antimicrobial susceptibility Testing Breakpoint
tables for interpretation of MICs and zone diameters versions 1.0 to 4.0.
http://www.eucast.org.
14. EUCAST guidelines for detection of resistance mechanisms and specific
resistances of clinical and/or epidemiological importance. Version 1.0. http://
www.eucast.org.
15. Midtvedt K, Hartmann A, Midtvedt T, Brekke IB. Routine perioperative
antibiotic prophylaxis in renal transplantation. Nephrol Dial Transplant. 1998;
13(7):1637–41.
16. Laftavi MR, Rostami R, Patel S, et al. Universal perioperative
antimicrobial prophylaxis is not necessary in kidney transplantation. Clin
Transpl. 2012;26:437.
17. Souza RM, Olsburg J. Urinary tract infection in the renal transplant patient.
Nat Clin Pract Nephrol. 2008;4(5):252–64.
18. Bodro M, Sanclemente G, Lipperheide I, et al. Impact of urinary tract
infections on short-term kidney graft outcome. Clin Microbiol Infect. 2015;
21(12):1104.e1–8.
19. Bodro M, Sanclemente G, Lipperheide I, et al. Impact of antibiotic resistance
on the development of recurrent and relapsing symptomatic urinary tract
infection in kidney recipients. Am J Transplant. 2015;15(4):1021–7.
20. Abboud CS, Bergamasco MD, Sousa EE, Zandonadi Ede C, Cortez D.
Successful use of gentamycin as an antibiotic prophylaxis regimen to
reduce the rate of healthcare-associated infections after renal
transplantation. Braz J Infect Dis. 2013;17(2):254–5.
21. Orlando G, Manzia TM, Sorge R, et al. One-shot versus multidose
perioperative antibiotic prophylaxis after kidney transplantation: a
randomized, controlled clinical trial. Surgery. 2015;157(1):104–10.
22. Mahajan SN, Ariza-Heredia EJ, Rolston KV, et al. Perioperative antimicrobial
prophylaxis for intra-abdominal surgery in patients with cancer: a
retrospective study comparing ertapenem and nonertapenem antibiotics.
Ann Surg Oncol. 2014;21(2):513–9.
23. Leng XS, Zhao YJ, Qiu HZ, et al. Ertapenem prophylaxis of surgical site
infections in elective colorectal surgery in China: a multicentre,
randomized, double-blind, active-controlled study. J Antimicrob
Chemother. 2014;69(12):3379–86.
24. Bora F, Aliosmanoglu I, Kocak H, Dinckan A, Uslu HB, Gunseren F,
Suleymanlar G. Drug interaction between tacrolimus and ertapenem in
renal transplantation recipients. Transplant Proc. 2012;44(10):3029–32.
25. Ruppé E, Lixandru B, Cojocaru R, et al. Relative fecal abundance of
extended-spectrum-β-lactamase-producing Escherichia coli strains and their
occurrence in urinary tract infections in women. Antimicrob Agents
Chemother. 2013;57(9):4512–7.
26. Rodriguez-Bano J, Picon E, Gijon P, Hernandez JR, Cisneros JM, Pena C, et al.
Risk factors and prognosis of nosocomial bloodstream infections caused by
extended-spectrum-beta-lactamase-producing Escherichia coli. J Clin
Microbiol. 2010;48(5):1726–31.
27. Linares L, Garcia-Goez JF, Cervera C, Almela M, Sanclemente G, Cofan F, et
al. Early bacteremia after solid organ transplantation. Transplant Proc. 2009;
41(6):2262–4.
28. Bert F, Larroque B, Paugam-Burtz C, et al. Pretransplant fecal carriage of
extended-spectrum β-lactamase-producing Enterobacteriaceae and
infection after liver transplant, France. Emerg Infect Dis. 2012;18(6):908–16.
29. Safdar N, Said A, Lucey MR. The role of selective digestive decontamination
for reducing infection in patients undergoing liver transplantation: a
systematic review and meta-analysis. Liver Transpl. 2004;10(7):817–27.
30. Boyer A, Doussau A, Thiébault R, et al. Pseudomonas aeruginosa acquisition
on an intensive care unit: relationship between antibiotic selective pressure
and patients’ environment. Crit Care. 2011;15(1):R55.
31. Cobos-Trigueros N, Solé M, Castro P, et al. Acquisition of Pseudomonas
aeruginosa and its resistance phenotypes in critically-ill medical
patients: role of colonization pressure and antibiotic exposure. Crit Care.
2015;19(1):218.
32. Linares L, Cervera C, Cofán F, et al. Risk factors for infection with
extended-spectrum and AmpC beta-lactamase-producing gram-negative
rods in renal transplantation. Am J Transplant. 2008;8(5):1000–5.
33. Rodriguez-Osorio CA, Sanchez-Martinez CO, Araujo-Melendez J, et al.
Impact of ertapenem on antimicrobial resistance in a sentinel group of
gram-negative bacilli: a 6 year antimicrobial resistance surveillance
study. J Antimicrob Chemother. 2015;70(3):914–21.
34. Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem.
J Antimicrob Chemother. 2003;52(3):331–44.
Sanclemente et al. BMC Nephrology          (2019) 20:274 Page 9 of 10
35. Mainardi JL, Hugonnet JE, Rusconi F, et al. Unexpected inhibition of
peptidoglycan LD-transpeptidase from Enterococcus faecium by the
beta-lactam imipenem. J Biol Chem. 2007;282(42):30414–22.
36. Dubée V, Arthur M, Fief H, et al. Kinetic analysis of Enterococcus faecium
L,D-transpeptidase inactivation by carbapenems. Antimicrob Agents
Chemother. 2012;56(6):3409–12.
37. Espinar MJ, Miranda IM, Costa-de-Oliveira S, et al. Urinary tract infections in
kidney transplant patients due to Escherichia coli and Klebsiella
pneumoniae-producing extended-Spectrum β-lactamases: risk factors and
molecular epidemiology. PLoS One. 2015;10(8):e0134737.
38. Korth J, Kukalla J, Rath PM, et al. Increased resistance of gram-negative
urinary pathogens after kidney transplantation. BMC Nephrol. 2017;18(1):164.
39. Kritikos A, Manuel O. Bloodstream infections after solid-organ
transplantation. Virulence. 2016;7(3):329–40.
40. Bodro M, Sabé N, Tubau F, Lladó L, Baliellas C, Roca J, Cruzado JM, Carratalà J. Risk
factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens
in solid-organ transplant recipients. Transplantation. 2013;96(9):843–9.
41. Tacconelli E, Cataldo MA, Dancer SJ, et al. ESCMID guidelines for the
management of the infection control measures to reduce transmission of
multidrug-resistant gram-negative bacteria in hospitalized patients. Clin
Microbiol Infect. 2014;20(Suppl 1):1–55.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Sanclemente et al. BMC Nephrology          (2019) 20:274 Page 10 of 10
